Ibrutinib-induced cardiomyopathy

Ibrutinib-induced cardiomyopathy

The use of ibrutinib for the treatment of chronic lymphocytic leukemia (CLL) and other hematologic malignancies is blooming. Atrial fibrillation is a known side effect of ibrutinib but cardiomyopathy was not reported previously. We present an 88-year-old man with CLL who was admitted to the hospital...

Full description

Bibliographic Details
Main Authors:	Htay Htay Kyi, Yazan Zayed, Samer Al Hadidi
Format:	Article
Language:	English
Published:	Greater Baltimore Medical Center 2019-01-01
Series:	Journal of Community Hospital Internal Medicine Perspectives
Subjects:	CLL heart failure Ibrutinib Leukemia side effects
Online Access:	http://dx.doi.org/10.1080/20009666.2018.1555432

Similar Items

Ibrutinib-Induced Skin Rash
by: Sudhir Kirar, et al.
Published: (2021-02-01)

Comparison of the blood immune repertoire with clinical features in chronic lymphocytic leukemia patients treated with chemoimmunotherapy or ibrutinib
by: Baustin M. Welch, et al.
Published: (2023-12-01)

SUCCESSFUL LONG-TERM REMISSION IN AGGRESSIVE YOUNG-ONSET CHRONIC LYMPHOCYTIC LEUKEMIA WITH IBRUTINIB AND VENETOCLAX: A DECADE-LONG CASE STUDY
by: Naciye Nur Tozluklu, et al.
Published: (2024-12-01)

Management of infections for patient treated with ibrutinib in clinical practice
by: Claudia Baratè, et al.
Published: (2024-09-01)

Ibrutinib-Induced Cardiac Tamponade in Chronic Lymphocytic Leukemia
by: Keisuke Kidoguchi, et al.
Published: (2021-02-01)

Ibrutinib associated cardiovascular events in a patient wearing an implanted loop recorder
by: Daniel Rivera, et al.
Published: (2021-06-01)

Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia
by: Elizabeth M. Muhowski, et al.
Published: (2022-11-01)

The regulation of tumor‐suppressive microRNA, miR‐126, in chronic lymphocytic leukemia
by: Daphne Guinn, et al.
Published: (2017-04-01)

A ROR1 small molecule inhibitor (KAN0441571C) induced significant apoptosis of ibrutinib‐resistant ROR1+ CLL cells
by: Amineh Ghaderi, et al.
Published: (2021-08-01)

Real-World Clinical Outcomes and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Single-Center Retrospective Study
by: Ana-Maria Moldovianu, et al.
Published: (2023-02-01)

Ibrutinib-Associated Leukocytoclastic Vasculitis in a Patient with Chronic Lymphocytic Leukemia
by: Ayşe Kaya, et al.
Published: (2024-03-01)

A real‐world study to assess the association of cardiovascular adverse events (CVAEs) with ibrutinib as first‐line (1L) treatment for patients with chronic lymphocytic leukaemia (CLL) in the United States
by: Anthony Mato, et al.
Published: (2023-02-01)

The Novel Anti-Cancer Agent, SpiD3, Is Cytotoxic in CLL Cells Resistant to Ibrutinib or Venetoclax
by: Alexandria P. Eiken, et al.
Published: (2024-08-01)

İbrutinib Sonrası Gelişen Dev Ekimoz ve Hematom: Olgu Sunumu
by: Aynur Uğur Bilgin, et al.
Published: (2017-03-01)

Real-world experience of ibrutinib therapy in relapsed chronic lymphocytic leukemia: results of a single-center retrospective analysis
by: Nuttall E, et al.
Published: (2019-07-01)

Synergistic effect of venetoclax and ibrutinib on ibrutinib-resistant ABC-type DLBCL cells
by: Fengbo Jin, et al.
Published: (2024-10-01)

Two Distinct Clinical Patterns of Ibrutinib-to-Venetoclax Transition in Relapsed Chronic Lymphocytic Leukemia Patients
by: Isacco Ferrarini, et al.
Published: (2022-04-01)

EXPERIENCE WITH IBRUTINIB IN PATIENTS WITH REFRACTORY AND RECURRENT B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA
by: T. V. SOROKINA, et al.
Published: (2017-06-01)

Pharmacists’ Role in Managing Patients with Chronic Lymphocytic Leukemia
by: Kevin Y. Chen, et al.
Published: (2020-03-01)

Safety and efficacy of ibrutinib in a patient with severe renal impairment
by: Kalman Filanovsky, et al.
Published: (2017-09-01)

Major hemorrhage in chronic lymphocytic leukemia patients in the US Veterans Health Administration system in the pre‐ibrutinib era: Incidence and risk factors
by: Peter Georgantopoulos, et al.
Published: (2019-05-01)

Effectiveness and Safety of Ibrutinib for Chronic Lymphocytic Leukemia in Routine Clinical Practice: 3-Year Follow-up of the Belgian Ibrutinib Real-World Data (BiRD) Study
by: Ann Janssens, et al.
Published: (2022-10-01)

Targeted therapies in CLL/SLL and the cumulative incidence of infection: A systematic review and meta-analysis
by: Stephanos Vassilopoulos, et al.
Published: (2022-09-01)

Possibilities of therapy recurrent b-cell chronic lymphocytic leukemia associated with autoimmune complications: data from literature and personal observation
by: S. R. Goryacheva, et al.
Published: (2018-07-01)

Search for Synergistic Drug Combinations to Treat Chronic Lymphocytic Leukemia
by: Eleonora Ela Hezkiy, et al.
Published: (2022-11-01)

Multifocal periungual granulation tissue related to ibrutinib therapy
by: Aatman Shah, MD, et al.
Published: (2020-02-01)

Ibrutinib-Induced Pancreatitis in Patients with Waldenstrom Macroglobulinemia
by: Nurhilal Büyükkurt, et al.
Published: (2023-06-01)

BCR SIGNALING INHIBITORS: AN OVERVIEW OF TOXICITIES ASSOCIATED WITH IBRUTINIB AND IDELALISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
by: Lorenzo Falchi, et al.
Published: (2016-02-01)

Hepatitis B Virus Reactivation under Ibrutinib Treatment in a Patient with Chronic Lymphocytic Leukemia
by: Gülşen İskender, et al.
Published: (2020-08-01)

A New Scoring System for the Evaluation of Ibrutinib-Associated Arrhythmias in Chronic Lymphocytic Leukemia: The ACEF Score
by: İlhan Koyuncu, et al.
Published: (2024-06-01)

Efficacy and Safety of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia: Retrospective Analysis of Real-Life Data
by: Anıl Tombak, et al.
Published: (2021-12-01)

Successful Management of Ibrutinib-Induced Thrombocytopenia in a Patient with Chronic Lymphocytic Leukemia: No Interruption, Only Reduction
by: Simge Erdem, et al.
Published: (2024-03-01)

Successful Treatment of Chronic Lymphocytic Leukemia Multifocal Central Nervous System Involvement with Ibrutinib
by: Anna Christoforidou, et al.
Published: (2018-05-01)

Hodgkin's variant of Richter transformation during ibrutinib therapy: A case report and review of the literature
by: Carolina Afonso, et al.
Published: (2022-10-01)

Ibrutinib impairs IGF-1-dependent activation of intracellular Ca handling in isolated mouse ventricular myocytes
by: Daniel Tarnowski, et al.
Published: (2023-08-01)

Ibrutinib continues to influence the therapeutic landscape of chronic lymphocytic leukemia: new data presented at ASCO 2017
by: Stefano Molica
Published: (2017-08-01)

Emergence of overt myeloma in a patient with chronic lymphocytic leukemia on ibrutinib therapy
by: Ayad M. Al‐Katib, et al.
Published: (2020-09-01)

The Role of BTK Inhibition in the Treatment of Chronic Lymphocytic Leukemia: A Clinical View
by: Tambaro FP, et al.
Published: (2021-10-01)

Effects of ibrutinib on T-cell immunity in patients with chronic lymphocytic leukemia
by: Yanyan Liu, et al.
Published: (2022-08-01)

TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia
by: Maria Cristina Puzzolo, et al.
Published: (2021-04-01)